Israel - inglés - Ministry of Health

abic marketing ltd, israel - lamivudine as anhydrous; zidovudine - tablets - zidovudine 300 mg; lamivudine as anhydrous 150 mg - zidovudine - zidovudine - antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Malta - inglés - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - lamivudine, zidovudine - film-coated tablet - lamivudine 150 mg zidovudine 300 mg - antivirals for systemic use

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

rex medical ltd - zidovudine 100mg - capsule - 100 mg - active: zidovudine 100mg excipient: black ink bki001 colloidal silicon dioxide gelatin magnesium stearate maize starch microcrystalline cellulose purified talc sodium starch glycolate - zidovudine oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

rex medical ltd - zidovudine 10 mg/ml - oral solution - 10 mg/ml - active: zidovudine 10 mg/ml excipient: apple flavour 844430 citric acid monohydrate glycerol maltitol methyl hydroxybenzoate propyl hydroxybenzoate purified water - zidovudine oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.

Canadá - inglés - Health Canada

apotex inc - zidovudine - capsule - 100mg - zidovudine 100mg - nucleoside and nucleotide reverse transcriptase inhibitors

Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - lamivudine; zidovudine -

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets, usp a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. lamivudine and zidovudine tablets, usp are contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine and zidovudine tablets during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263.   risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine or zidovudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the g

Australia - inglés - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - lamivudine, quantity: 150 mg; zidovudine, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 4000 - combivir is indicated for use alone or in combination with other antiretroviral therapies in the treatment of hiv infection.

Estados Unidos - inglés - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - abacavir 300 mg - trizivir is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. limitations of use: trizivir is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to trizivir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir, lamivudine, or zidovudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 w

Estados Unidos - inglés - NLM (National Library of Medicine)

lupin limited - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. lamivudine and zidovudine tablet is contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. pregnancy category c pregnancy exposure registry: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine and zidovudine tablets during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry at 1-800-258-4263. fetal risk summary: there are no adequate and well-controlled trials of lamivudine and zidovudine in pregnant women. clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of hiv-1 infection to the fetus. animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and feta